Whether the glioma gene is not mutated is good or bad can not be fully confirmed, it is necessary to determine the grading of the glioma, according to the progress of the disease to determine the good or bad. The significance of genetic testing for patients with glioma is to determine whether targeted drug therapy is possible. Patients with mutations can be given targeted drug therapy to prolong the survival time of glioma patients. Patients without mutations are not suitable for targeted drug therapy. However, there is no direct relationship between the presence of gene mutations in patients with glioma and the degree of severity of the disease. For the severity of glioma lesions need to be judged according to the grading, the degree of malignancy with the increase in the level of the malignant degree gradually increased, the disease progression to grade 4 when the prognosis is poor, the survival period is significantly shortened, the second level of glioma patients early detection to give early treatment, the 5-year survival rate increased significantly. For patients with glioma, it is recommended to consult the neurosurgery department of regular hospitals.